比索洛尔联合厄贝沙坦治疗慢性心力衰竭患者的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical effect of Bisoprolol combined with Irbesartan on patients with chronic heart failure.Methods A total of 88 patients with chronic heart failure admitted to our hospital from July 2018 to July 2019 were selected as research objects.According to the single or even number of hospital beds,they were divided into treatment group (44 cases) and control group (44 cases).The control group was treated with Irbesartan.The treatment group was treated with Bisoprolol and Irbesartan.The cardiac function index,blood pressure,serum B-type brain natriuretic peptide (BNP) and high sensitivity C-reactive protein (hs-CRP) levels of the two groups were compared.Results The left ventricular ejection fraction (LVEF) level in the treatment group was higher than that in the control group,with statistical significance (P<0.05),while the left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD) levels in the treatment group were lower than those in the control group,with statistical significances (P<0.05).The levels of BNP and hs-CRP in the treatment group were lower than those in the control group after treatment,and the differences were statistically significant (P<0.05).The systolic blood pressure (SBP),diastolic blood pressure (DBP) and pulse pressure difference after treatment in the treatment group were lower than those in the control group,with statistically significant differences (P<0.05).The total effective rate of the treatment group was higher than that of the control group,with statistically significant difference (P<0.05).Conclusion The combination of Bisoprolol and Irbesartan has definite effect on the treatment of chronic heart failure,which can effectively improve the cardiac function index of patients,regulate the blood pressure level of patients,optimize the serum BNP and hs-CRP levels of patients,and has higher application value in clinical practice.

Key words： Chronic heart failure Irbesartan Bisoprolol Cardiac function index Blood pressure

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Xiao-qiang
	HU Liang-ming

Cite this article:

HUANG Xiao-qiang,HU Liang-ming. Clinical effect of Bisoprolol combined with Irbesartan in the treatment of patients with chronic heart failure[J]. 中国当代医药, 2020, 27(14): 65-67转71.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I14/65

[1]	孟立平，郭航远，蒋承建.慢性心力衰竭药物治疗研究进展[J].中国全科医学，2015，18（23）：2870-2872.
[2]	张振英，孙兴国，席家宁，等.心肺运动试验在慢性心力衰竭患者高强度个体化运动康复处方制定和运动康复效果评估中的作用研究[J].中国全科医学，2016，19（17）：2061-2067.
[3]	姜雪.厄贝沙坦和比索洛尔联合治疗慢性心力衰竭的临床疗效评价[J].中国处方药，2016，14（2）：83-84.
[4]	陈东运，王芸芝，孙巧丽.比索洛尔联合厄贝沙坦用于慢性心力衰竭治疗的可行性研究[J].中国现代药物应用，2016，10（20）：103-104.
[5]	黄梦红，肖飞.慢性心力衰竭应用比索洛尔联合厄贝沙坦治疗的有效性评析[J].中国继续医学教育，2017，9（1）：151-152.
[6]	李国建.比索洛尔联合厄贝沙坦用于慢性心力衰竭治疗的可行性研究[J].北方药学，2017，14（7）：45-52.
[7]	侯文启.比索洛尔联合厄贝沙坦对慢性心衰患者血清hs-CRP、BNP水平的影响[J].中国合理用药探索，2017，14（10）：5-7.
[8]	张美丽.厄贝沙坦联合比索洛尔治疗慢性心力衰竭的临床疗效[J].实用妇科内分泌杂志（电子版），2017，4（28）：14，16.
[9]	冯英.慢性心力衰竭应用比索洛尔联合厄贝沙坦治疗的可行性研究[J].中国医药指南，2018，16（11）：172-173.
[10]	苗艳军.厄贝沙坦联合比索洛尔对慢性心力衰竭患者心功能及血清hs-CRP、BNP水平变化的影响[J].首都食品与医药，2018，25（18）：54-55.
[11]	朱鼎粤.充血性心力衰竭合并室性心早搏患者实施厄贝沙坦联合比索洛尔治疗效果及其对血清BNP的影响分析[J].吉林医学，2019，40（5）：936-938.
[12]	黄振东.厄贝沙坦片联合比索洛尔治疗老年高血压伴心力衰竭的心脏结构及心功能的影响[J].中外医疗，2019，38（12）：107-109.
[13]	罗良涛，郭淑贞，张鹏，等.冠心病慢性心力衰竭合并高血压患者证候要素和证候分布特点[J].北京中医药大学学报，2017，40（7）：607-612.
[14]	邸军军，岳玉国，赵新国，等.慢性心力衰竭患者肺部感染的临床特征及免疫功能分析[J].中华医院感染学杂志，2017，27（6）：1263-1266，1278.
[15]	罗勇.心脏瓣膜置换术后应用厄贝沙坦联合比索洛尔对风湿性心脏瓣膜病患者心肾功能及炎性因子水平的影响[J].世界复合医学，2019，5（4）：108-111.